safety and efficacy of anlotinib, and quantify its treatment effect in advanced metastatic colorectal cancer patients. 150 advanced metastatic colorectal cancer patients received third-line or more treatment ... that…
that originates in the colon or rectum is colorectal cancer. Stadium 0, which is extremely early cancer, to stage 4, metastatic colorectal cancer is stage 4 of this form ... cancer. Colorectal metastatic cancer is a…
Patients with metastatic colorectal cancer (mCRC) have typically overall survival (OS) of approximately 30 months, if multi disciplinary team approach was applied. The first-line treatment comprises cytotoxic agents
contains clinical efficacy of bevacizumab in conjunction with oxaliplatin and capecitabine in managing metastatic colorectal cancer. The study population consisted of 150 individuals diagnosed with metastatic colorectal…
diagnosed malignancies in men and women and despite recent advances the prognosis of metastatic colorectal cancer remains poor. A better understanding of the molecular pathways that characterize tumor growth ... cancer…
epidermal growth factor receptor, has proven to be efficient in the treatment of metastatic colorectal cancer. We made a prospective study of the efficacy and toxicities of cetuximab-combination first ... versus…
study investigated the absence of metabolic response to oxaliplatin-based therapy in progressive metastatic colorectal cancer as a possible risk factor. Ten patients were selected: five cases (metastatic colon cancer
Metastatic colorectal cancer is the second leading cause of cancer-related death in the Western population. New therapies have been developed at a rapid pace in the past 15 years ... regimens. Elderly patients with a…
Growth Factor (VEGF) in peripheral blood vessels and the prognosis of patients with Metastatic Colorectal Cancer (MCC). Peripheral blood samples of a total of 60 MCC patients treated
Background: The effectiveness of Bevacizumab has been demonstrated for the treatment of metastatic colorectal cancer. However, the minimum number of bevacizumab cycles needed to improve overall survival is unknown…
Objective: While the clinical effect of regorafenib for third-line metastatic colorectal cancer has been established, the economic effect of adopting the new therapy (regorafenib) is still unclear. The present
colorectal cancer (CRC) is P53. The goal of the current investigation was to establish a reliable estimate of the prognostic significance of p53 mutations in individuals with metastatic
oxaliplatin, fluorouracil, and lleucovorin regimen (FOLFOX6) in Japanese patients with previously untreated, unresectable metastatic colorectal cancer because oxaliplatin of FOLFOX6 was given at a previously untested…
impact of age on receipt of chemotherapy among low-income individuals with metastatic colorectal cancer. Data Sources/Study Setting: North Carolina Medicaid enrollees with metastatic colorectal cancer diagnosed from
Several steps forwards have been made in the treatment of metastatic Colorectal Cancer (mCRC) in the last years. The introduction of new active drugs, such as regorafenib in heavily Pretreated
inhibitor which is anti- angiogenic, and has shown promising anti-tumor activity in Metastatic Colorectal Cancer (mCRC). Reports have shown that response to regorafenib is more favourable in patients with ... mutation…
Colorectal cancer is the second leading cause of death from cancer in the developed countries. Although great efforts have been made to early ... diagnosis a relevant number of cases will present metastases. The natural…
Treatment of human metastatic colorectal cancer (mCRC) remarkably changed over the past two decades. The use of novel therapies and more complex treatment strategies have contributed to progressively increase
patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer (CRC), the inhibition of programmed death-1 (PD-1) pathway has achieved promising response [1]. PD-1 is an immune ... inhibitory signal…
diagnostic testing has become an integral part of the evaluation of patients with metastatic colorectal cancer (CRC). However, expanded mutational testing often identifies mutations with unclear clinical, therapeutic or…
Background: KRAS testing is a critical initial step of the treatment for metastatic colorectal cancer patients. However, recent clinical trials have raised the issue of whether patient selection as determined
phase III studies have addressed the role of chemotherapy or chemo/biotherapy in metastatic colorectal cancer (mCRC); most of these studies planned their treatment to be continued until disease progression
cetuximab and irinotecan as a biweekly regimen in treatment of elderly patients with metastatic colorectal cancer (m-CRC). Patients & Methods: 49 elderly patients (Ã?¢Ã?Â?Ã?¥65 years) with
prognostic and predictive role of circulating tumor cells (CTCs) in KRAS wild-type metastatic Colorectal Cancer (mCRC) patients treated with panitumumab after progression on cetuximab. Methods: Panitumumab
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.